Christina T. Roupas

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised PetIQ (Nasdaq: PETQ), a leading pet medication, health and wellness company, on its definitive merger agreement with Bansk Group, pursuant to which Bansk Group will acquire all outstanding shares of PetIQ’s common stock for $31 per share in an all-cash transaction valued at approximately $1.5 billion.

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.

Cooley advised COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, on the close of its $105 million Series A financing.

Cooley advised NETSTREIT on a $250 million sustainability-linked senior unsecured term loan facility agented by Truist Bank, as well as the amendment and extension of its existing $175 million senior unsecured term loan agented by Wells Fargo Bank. NETSTREIT is a real estate investment trust based in Dallas, Texas, that acquires single-tenant net lease retail properties across the US. Michael Tollini, Christina Roupas, Addison Pierce, Sai Yarramalla, Margaret Barreto and Leah Duncan led the Cooley team.